Cell and gene therapies (CGTs) are transforming the landscape of rare diseases, offering unprecedented opportunities to address long-standing unmet medical needs. As the biopharmaceutical industry increasingly invests in these innovative therapies, the number of clinical trials and approvals for orphan diseases has surged, reflecting a growing recognition of their potential to change patient outcomes significantly.
This evolution is not just a boon for patients; it also presents a myriad of challenges and considerations for pharma professionals involved in regulatory, quality assurance, and supply chain management. The complexity of CGTs necessitates robust frameworks for compliance and quality control, as well as strategic sourcing to ensure the availability of raw materials and advanced manufacturing capabilities. As the sector evolves, stakeholders must remain agile and informed to navigate the regulatory landscape effectively and capitalize on the opportunities presented by this rare disease revolution.
Open the full market picture for your next decision →
